HKUCTR-2993Recruitment Completed
Untitled Trial
A Phase 2a open-label study of the oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect in chronic Hepatitis B (CHB) patients in combination with pegylated interferon alpha2a (peg-IFN) alone and with entecavir (ETV)
ENYO Pharma SAPhase 2HKU CLINICAL TRIALS REGISTRYdrug
VerifiedHKU CLINICAL TRIALS REGISTRY
Study focus
- Disease/Condition
- Infection
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- ENYO Pharma SA
- Location
- China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- N/A
- End date
- Sep 05, 2021
ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsInfection following immunizationOther infectious diseasesViral infection, unspecified
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2993
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2993 through Pure Global AI's free database. This Phase 2 trial is sponsored by ENYO Pharma SA and is currently Recruitment Completed. The study focuses on Infection.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.